MiNK Therapeutics, Inc. Q4 Loss Decreases, But Misses Estimates

MiNK Therapeutics, Inc. (INKT) reported Loss for fourth quarter that decreased from last year but missed the Street estimates.

The company's bottom line totaled -$2.5 million, or -$0.62 per share. This compares with -$5.5 million, or -$1.58 per share, last year.

Analysts on average had expected the company to earn -$0.5 per share. Analysts' estimates typically exclude special items.

MiNK Therapeutics, Inc. earnings at a glance (GAAP) :

-Earnings: -$2.5 Mln. vs. -$5.5 Mln. last year.
-EPS: -$0.62 vs. -$1.58 last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com